Mirataz

RSS

mirtazapine

Authorised
This medicine is authorised for use in the European Union.

Overview

Mirataz is a medicine used to produce an increase in bodyweight in cats with long-term conditions known to cause poor appetite and weight loss. It contains the active substance mirtazapine.

This EPAR was last updated on 02/02/2021

Authorisation details

Product details
Name
Mirataz
Agency product number
EMEA/V/C/004733
Active substance
mirtazapine
International non-proprietary name (INN) or common name
mirtazapine
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QN06AX11
Publication details
Marketing-authorisation holder
Dechra Regulatory B.V.
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
10/12/2019
Contact address

Handelsweg 25
5531 AE Bladel
The Netherlands

Product information

15/01/2021 Mirataz - EMEA/V/C/004733 - IB/0003/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Psychoanaleptics

  • Antidepressants in combination with psycholeptics

Therapeutic indication

For bodyweight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings
1 rating